Poland· PL-100108272
Simvacard 20
A simvastatin product containing simvastatinum, registered in Poland by Zentiva, k.s.. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Simvastatin is registered in 17 of 19 countries.
Countries holding a registration under ATC C10AA01 (simvastatin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 10 of them publish a price we can compare per daily dose
Simvastatin · ATC C10AA01
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of simvastatin costs, country by country.
Normalised to the WHO defined daily dose (30 mg), the median price runs from $0.17 in France to $0.97 in Switzerland — a ×5.9 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Simvastatin · price per daily dose (30 mg)
USD · FX 28 Sept 2026
- CH Switzerland$0.97
- IT Italy$0.33
- FR France$0.17
The record
At a glance
URPL (Poland)- Active substance
- Simvastatinum
- Manufacturer
- Zentiva, k.s.
- Country
- Poland (PL)
- ATC code
- C10AA01
- ATC class
- Simvastatin
- Defined daily dose
- 30 mg, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
1 priced- gtin0590999094021928 szt.PLN 10.74
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
889 interactions on record for simvastatin.
Graded by severity as the source publishes them — 59 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Simvastatin · interactions on record
889 records
- 59 severe
- 253 moderate
- 10 minor
- 513 info
Most severe, free to view
- LonafarnibA16AX20severe
- AmiodaroneC01BD01severe
- DronedaroneC01BD07severe
- RanolazineC01EB18severe
54 more interactions with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under C10AA01
Simvastatin, as other registers publish it.
- ItalyALPHEUSS.F. GROUP S.R.L.
- ItalyALPHEUSS.F. GROUP S.R.L.
- PolandApo-Simva 10Aurovitas Pharma Polska Sp. z o.o.
- PolandApo-Simva 20Aurovitas Pharma Polska Sp. z o.o.
- PolandApo-Simva 40Aurovitas Pharma Polska Sp. z o.o.
- CanadaAPO-SIMVASTATINAPOTEX INC
- CanadaAPO-SIMVASTATINAPOTEX INC
- CanadaAPO-SIMVASTATINAPOTEX INC
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/efc4a93f-cddb-4371-8599-72fa343442db GET /v1/drugs/efc4a93f-cddb-4371-8599-72fa343442db?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "20 mg",
"packaging": "05909990940219 ¦ Rp ¦ 19324\n28 tabl.",
"substance": "Simvastatinum 20 mg",
"common_name": "Simvastatinum",
"pl_product_id": "100108272",
"pozwolenie_nr": "09402",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about simvastatin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.